--- title: "U.S. stock market midday update: Intercure's stock price soared 16.48%, trading volume surged, and sector trends have attracted market attention?" type: "News" locale: "en" url: "https://longbridge.com/en/news/271347634.md" description: "Intercure rose 16.48%; Eli Lilly fell 0.42%, with a trading volume of USD 792 million; Johnson & Johnson rose 0.02%, with a trading volume of USD 370 million; Novo Nordisk rose 2.26%, with a trading volume of USD 244 million; AstraZeneca rose 0.13%, with a market value of USD 285.5 billion" datetime: "2026-01-02T16:07:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/271347634.md) - [en](https://longbridge.com/en/news/271347634.md) - [zh-HK](https://longbridge.com/zh-HK/news/271347634.md) --- # U.S. stock market midday update: Intercure's stock price soared 16.48%, trading volume surged, and sector trends have attracted market attention? **U.S. Stock Market Midday Update** Intercure, up 16.48%, with increased trading volume and no significant news recently. The trading is active, with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks Ranked High in Industry Trading Volume** Eli Lilly down 0.42%, with increased trading volume. Based on recent key news: 1. On December 31, Eli Lilly was listed as one of the best pharmaceutical stocks for 2026, expected to play a significant role in the obesity drug market in India. Analysts believe Eli Lilly's leading position in the obesity drug market will continue to drive its stock price up. 2. On January 2, Celltrion signed a $473 million production contract with Eli Lilly, expected to accelerate Eli Lilly's revenue growth. This collaboration is expected to enhance Eli Lilly's operating profit and drive the stock price up. 3. On December 31, Eli Lilly's stock price rose nearly 40% for the year, with investors focusing on the potential approval and 2026 launch of its GLP-1 oral medication. Analysts predict Eli Lilly will achieve 20% sales growth, primarily driven by the diabetes drug Mounjaro and the obesity drug Zepbound. The obesity drug market is highly competitive, with significant policy impacts. Johnson & Johnson up 0.02%, with increased trading volume. Based on recent key news: 1. On January 2, Johnson & Johnson announced a first-quarter 2026 dividend of $1.30 per share, unchanged from the previous one, showing stable cash returns and attracting the attention of dividend investors. Source: Businesswire 2. On January 1, analysts pointed out that Johnson & Johnson is favored by investors as a high-dividend stock, especially in the context of Federal Reserve interest rate cuts, making stable dividend stocks more attractive. Source: Barron's 3. On December 30, Johnson & Johnson failed to transfer its talc powder lawsuits to bankruptcy proceedings, leading to an increase in ovarian cancer claims, which may affect the company's legal risks. Source: Wisner Baum. High-dividend stocks benefit from the Federal Reserve's interest rate cuts. Novo Nordisk up 2.26%. Based on recent key news: 1. On January 2, clinical trials of Novo Nordisk's oral version of Wegovy showed significant weight loss effects, boosting market confidence in its products. After 64 weeks of continuous medication, the average weight reduction reached 16.6%, positioning Novo Nordisk to regain market share. Source: CNBC 2. On January 2, the Supreme People's Court of China upheld the validity of Novo Nordisk's semaglutide patent, enhancing its intellectual property protection in the Chinese market. This ruling boosts the company's confidence in the Chinese market and encourages further development of innovative drugs. Source: Company statement 3. On January 1, Novo Nordisk received FDA approval for the oral version of its weight loss drug Wegovy, which is seen as one of the key themes the company will face in 2026, further solidifying its position in the weight loss drug market. Source: FDA announcement. The weight loss drug market is highly competitive, with enhanced policy support **Stocks Ranked Among the Top by Market Capitalization in the Industry** AstraZeneca rose by 0.13%. The stock price of AstraZeneca increased slightly with a larger trading volume, indicating enhanced market confidence in its future performance. There have been no significant news recently; trading is active with clear capital flow. Considering the sector and industry trends, the stock shows notable volatility, and the specific reasons need further observation. The pharmaceutical industry has recently performed steadily, with significant capital inflow. no\_news ### Related Stocks - [INCR.US](https://longbridge.com/en/quote/INCR.US.md) ## Related News & Research - [Trump purchased Eli Lilly stock as policies favored its drugs](https://longbridge.com/en/news/286791021.md) - [Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report](https://longbridge.com/en/news/286951567.md) - [Eric Trump denial challenged by filings showing timed stock buys](https://longbridge.com/en/news/286953419.md) - [Eli Lilly Among Petitioners Denied Certiorari as Supreme Court Rejects Multiple Appeals](https://longbridge.com/en/news/286789989.md) - [Eli Lilly and Company (NYSE:LLY) Stock Acquired Rep. Byron Donalds](https://longbridge.com/en/news/286648731.md)